Home

User Panes

August 21, 2017

The Food and Drug Administration declared that it would require strong new warnings that the combined use of opioid medications and benzodiazepines, a class of anti-anxiety medications can dangerously suppress breathing and cause coma or death. Thus, the stronger warning is required just to ensure the public that the combination can be dangerous.

FDA
4min read    
August 21, 2017

FDA announced that the safety labeling changes (SLC) program will be managed by the Center for Drug Evaluation and Research’s (CDER’s) Office of Communications (OCOMM). OCOMM has established a new “Drug Safety Labeling Changes (SLC)” database that provides these data to the public in downloadable and searchable formats.

FDA
4min read    
August 21, 2017

There is a hope on the very horizon for people suffering from low back pain. A relatively new procedure known as minimally invasive nerve-ablating procedure seems to be effective in treating some forms of back pain and may offer a new treatment option.

FDA
7min read    
August 21, 2017

Eli Lilly proved its victory for acquired FDA approval for blockbuster ixekizumab. There is a hope that will compete against a new wave of rival therapies for psoriasis. This drug would be sold as Taltz.

FDA
8min read    
August 21, 2017

Cardiovascular risks possess a great threat when one takes up the arthritis drugs. Thus, the researchers may be on their way to finding safer drugs for arthritis treatment that don't lead to potentially harmful cardiovascular side effects.

European Medicines Agency
5min read    
Key Take-Away:

 A 800 mg/day pharmaceutical-grade Chondroitin sulphate was found to be better than placebo and similar to celecoxib in alleviating pain and enhancing function in patients with symptomatic knee osteoarthritis (OA) over 6 months.

Osteoarthritis is one of the most common musculoskeletal disorders that significantly impact the quality of life of people suffering from it.  It is known to be a chief cause of pain, loss of funct

Ann Rheum Dis 2017; 0:1–7.
24min read    

Medication-overuse headache (MOH) is a debilitating condition in which frequent and prolonged use of medication for the acute treatment of pain results in the worsening of the headache. According to the International Classification of Headache Disorders, 3rd Edition, Beta (ICHD-3,''MOH is defined as the headache occurring on 15 or more days per month developing as a consequence of regular overuse of acute or symptomatic headache medication (on 10 or more, or 15 or more days per month, depending on the medication) for more than 3 months''. Prevalence is often reported as 1–2% but can be as high as 7% overall, with higher proportions among women and in those with a low socioeconomic position. It is not as prevalent as tension type headache or migraine but it is very disabling. The pathophysiology is complex and not completely known. It involves genetic and behavioral factors.

13min read    

Dysmenorrhea, a painful menstruation, is a common gynecological condition which usually affects the women in the reproductive years. Menstrual cramps can occur a few days prior to the menstruation or even during the menstruation. Dysmenorrhea is further classified into 2 subcategories based on the history and the examination:

  • Primary dysmenorrhea which occurs in the absence of pelvic pathology
  • Secondary dysmenorrhea which occurs in the presence of pelvic pathology
12min read    

Occurrence of headache is very common nowadays, even in kids. Parents usually consider these headaches as a severe problem in kids. Physical examination by doctor is preferred, that help decide whether neuro-imaging is required or not. Mostly, based on the diagnostic reports, treatment of headache is initiated. 

16min read    

Ankylosing spondylitis (AS) is a chronic immune-mediated inflammatory disease with worldwide prevalence of about 0.2–1.4%.

Arthritis & Rheumatology 2016;68(12):2901–2910
18min read    
Education

This guideline replaces the earlier CG88 i.e. Early management of persistent non-specific low back pain.

NICE
10 min read    
Education

Fibromyalgia syndrome is a common disorder characterized by multiple tender points, widespread deep muscle pain, sleep disturbance, fatigue and depression.

14min read    
Education

Gout involves problem with the purine metabolism. In this disease, the uric acid levels are increased (hyperuricemia) and urate crystals accumulates in joints and tissues of the body.

NICE
6 min read    
Education

Syndesmotic injuries at the ankle joint are injuries to the ligaments that connect the tibia and fibula.

NICE
10 min read    
Education

Fibromyalgia is a syndrome which is indicated by chronic widespread pain.

ACSAP
10 min read    
August 21, 2017

The Food and Drug Administration declared that it would require strong new warnings that the combined use of opioid medications and benzodiazepines, a class of anti-anxiety medications can dangerously suppress breathing and cause coma or death. Thus, the stronger warning is required just to ensure the public that the combination can be dangerous.

FDA
Key Take-Away:

 A 800 mg/day pharmaceutical-grade Chondroitin sulphate was found to be better than placebo and similar to celecoxib in alleviating pain and enhancing function in patients with symptomatic knee osteoarthritis (OA) over 6 months.

Osteoarthritis is one of the most common musculoskeletal disorders that significantly impact the quality of life of people suffering from it.  It is known to be a chief cause of pain, loss of funct

Ann Rheum Dis 2017; 0:1–7.
24min read    
Education

This guideline replaces the earlier CG88 i.e. Early management of persistent non-specific low back pain. Here, low back pain and sciatica has been estimated and managed in people aged 16 and over alongwith the physical, psychological, pharmacological and surgical treatments for the same. It is pivoted to improve people's quality of life, encouraging the most effective forms of care for low back pain and sciatica.

NICE
10 min read    
August 30, 2017 - September 1, 2017
Cork City , Ireland
1min read